Home

Jeff L Vacirca

CIK 1724161 · last filed 2026-08-14

Jeff L Vacirca is a corporate insider who has filed 31 SEC Form 4 insider transactions across 4 companies since 2017. The most recent filing, for CAI, was dated Aug 14, 2026. Across all open-market trades the lifetime net is +$1.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions. 21 SEC filings were submitted jointly with SPECTRUM PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.01M

Companies

4

Total Filings

31

Lifetime Open-Market Net

$1.11M

Filer Profile

Reported Address
4747 EXECUTIVE DRIVE
SUITE 510
SAN DIEGO, CA 92121
Related Filers
SPECTRUM PHARMACEUTICALS INC — 21 joint filings, latest 2023-08-01
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CAI Director 62,863 $31.98 $2.01M $501.4K 3 2026-08-14
Assertio Holdings, Inc. (ASRT) Delisted Director 10,077 $23.50 $236.8K $11.1K 3 2024-06-12
SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Director 0 $1.03 $0 $22.5K 20 2023-08-01
Odonate Therapeutics, Inc. (ODT) Delisted Director 23,231 $1.12 $26.0K $574.3K 5 2019-06-28

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 CAI Grant (A) +13,192 $0 EDGAR
2026-05-12 CAI Buy (P) +31,050 $501.4K EDGAR
2026-02-27 CAI Grant (A) +2,492 $50.0K EDGAR
2024-06-12 Assertio Holdings, Inc. (ASRT) Delisted Buy (P) +10,000 $11.1K EDGAR
2024-05-28 Assertio Holdings, Inc. (ASRT) Delisted Grant (A) +53,750 $0 EDGAR
2023-08-02 Assertio Holdings, Inc. (ASRT) Delisted Grant (A) +87,409 $0 EDGAR
2023-08-01 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Disp (D) −295,244 $0 EDGAR
2022-12-02 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Buy (P) +50,000 $22.5K EDGAR
2022-10-27 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Grant (A) +50,000 $21.5K EDGAR
2022-09-02 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Grant (A) +25,000 $0 EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.